Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is based in New Haven, Connecticut.

Trevi Therapeutics, Inc.

In a report released today, from Raymond James maintained a Buy rating on Trevi Therapeutics, with a price target of $40.00. The word on The Street...

Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Trevi Therapeutics (TRVI), Amneal Pharmaceuticals (AMRX) and Eras...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TRVI	$18.84	+1.95%	1.75M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TRVI	$18.84	+1.9%	1.75M
3
4
5
6

TRVI

Get Trevi Therapeutics, Inc. Data in Excel

Get Trevi Therapeutics, Inc. Data in Excel